Phibro Animal Health (NASDAQ:PAHC) Raised to Overweight at JPMorgan Chase & Co.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a research report issued to clients and investors on Monday, MarketBeat reports. The firm presently has a $35.00 price objective on the stock, up from their previous price objective of $25.00. JPMorgan Chase & Co.'s price target would suggest a potential upside of 12.40% from the stock's current price.

Other analysts have also recently issued research reports about the stock. BNP Paribas Exane raised shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a research note on Monday, June 16th. BNP Paribas raised shares of Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. Wall Street Zen raised shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Finally, Morgan Stanley set a $26.00 price objective on shares of Phibro Animal Health and gave the stock an "equal weight" rating in a research report on Wednesday, June 25th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Phibro Animal Health presently has an average rating of "Hold" and a consensus target price of $24.40.

Phibro Animal Health Price Performance

Shares of Phibro Animal Health stock traded down $0.25 during trading hours on Monday, reaching $31.14. The stock had a trading volume of 382,115 shares, compared to its average volume of 219,403. The stock's 50 day moving average is $24.31 and its 200 day moving average is $22.31. The firm has a market capitalization of $1.26 billion, a PE ratio of 39.92, a PEG ratio of 0.50 and a beta of 0.75. Phibro Animal Health has a twelve month low of $16.16 and a twelve month high of $31.82. The company has a current ratio of 2.91, a quick ratio of 1.23 and a debt-to-equity ratio of 2.67.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.52 by $0.11. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. The business had revenue of $347.80 million during the quarter, compared to the consensus estimate of $352.41 million. Equities analysts expect that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds have recently made changes to their positions in PAHC. Nuveen LLC acquired a new stake in Phibro Animal Health during the 1st quarter worth approximately $10,312,000. Invesco Ltd. lifted its holdings in Phibro Animal Health by 92.3% during the 1st quarter. Invesco Ltd. now owns 387,739 shares of the company's stock worth $8,282,000 after buying an additional 186,087 shares in the last quarter. Axecap Investments LLC acquired a new stake in Phibro Animal Health during the 1st quarter worth approximately $3,696,000. Millennium Management LLC lifted its holdings in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company's stock worth $7,733,000 after buying an additional 154,281 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Phibro Animal Health by 56.7% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 301,173 shares of the company's stock worth $6,325,000 after buying an additional 108,918 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.